Puma Biotechnology (PBYI) Operating Income (2010 - 2026)

Puma Biotechnology (PBYI) has 17 years of Operating Income data on file, last reported at -$3.8 million in Q1 2026.

• Quarterly Operating Income fell 196.08% year-over-year to -$3.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $29.5 million (down 20.84% YoY) and the FY2025 annual result came in at $37.3 million, up 20.45% from the prior year.
• Operating Income retreated to -$3.8 million in Q1 2026, from $17.1 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of $22.1 million in Q3 2024 to a low of -$3.8 million in Q1 2026.
• A 5-year average of $7.1 million and a median of $6.6 million in 2025 frame the typical range for Operating Income.
• Annual changes were most pronounced in 2023 — Operating Income surged 684.34% — and 2026, when it tumbled 196.08%.
• Tracing PBYI's Operating Income over 5 years: stood at $10.0 million in 2022, then soared by 47.74% to $14.8 million in 2023, then decreased by 9.68% to $13.4 million in 2024, then climbed by 27.99% to $17.1 million in 2025, then sank by 122.38% to -$3.8 million in 2026.
• The last three Operating Income figures came in at -$3.8 million (Q1 2026), $17.1 million (Q4 2025), and $9.6 million (Q3 2025), per Business Quant data.